Evidence map›Paper›PMID 31234300›Full record

ReviewAntioxidants (Basel, Switzerland)2019

Antidiabetic Effects of Hydroxytyrosol: In Vitro and In Vivo Evidence.

Filip Vlavcheski, Mariah Young, Evangelia Tsiani

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Antidiabetic potential of vanadium complexes combined with olive leaf extracts: a viable approach to reduce metal toxicity.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Hydroxytyrosol produced by engineeredExperimental biology and medicine (Maywood, N.J.) · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Filip VlavcheskiDepartment of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada. fvlavcheski@brocku.ca.ORCID 0000-0001-9615-1775
Mariah YoungDepartment of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada. my14ac@brocku.ca.
Evangelia TsianiDepartment of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada. ltsiani@brocku.ca.ORCID 0000-0003-4218-5851
Brock University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance, a pathological condition characterized by defects in insulin action leads to the development of Type 2 diabetes mellitus (T2DM), a disease which is currently on the rise that pose an enormous economic burden to healthcare systems worldwide. The current treatment and prevention strategies are considerably lacking in number and efficacy and therefore new targeted therapies and preventative strategies are urgently needed. Plant-derived chemicals such as metformin, derived from the French lilac, have been used to treat/manage insulin resistance and T2DM. Other plant-derived chemicals which are not yet discovered, may have superior properties to prevent and manage T2DM and thus research into this area is highly justifiable. Hydroxytyrosol is a phenolic phytochemical found in olive leaves and olive oil reported to have antioxidant, anti-inflammatory, anticancer and antidiabetic properties. The present review summarizes the current in vitro and in vivo studies examining the antidiabetic properties of hydroxytyrosol and investigating the mechanisms of its action.

Indexed as

antidiabeticantioxidantdiabeteshydroxytyrosolinsulin resistanceolive oilphenols

Identifiers

PMID31234300
PMCPMC6616959
OpenAlexW2949076062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.